HCA Healthcare, Inc. is a health care services company engaged in operating hospitals, freestanding surgery centers and emergency care facilities, urgent care facilities, walk-in clinics, diagnostic and imaging centers, radiation and oncology therapy centers, comprehensive rehabilitation and physical therapy centers, physician practices, home health, hospice, outpatient physical therapy home and community-based services providers, and various other facilities. The firm operates general and acute care hospitals that offer medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services, and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy. The company was founded by Dr. Thomas F. Frist, Jr in 1968 and is headquartered in Nashville, TN.
相关临床试验
0
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
暂无试验阶段数据
暂无试验数据
暂无试验数据
暂无批准数据
- Fitch Ratings reports nonprofit hospital operating margins rose to a median 1.5% this year, a third straight year of improvement before H.R. 1 policy changes take effect. - The One Big Beautiful Bill Act is projected to cut nearly $800 billion from Medicaid over a decade, with enrollment reductions and work requirements beginning in January 2027. - Safety net hospitals face steep losses, with MLK Community Hospital estimating an $80-$100 million annual hit and more than 300 rural hospitals at risk of closure. - The Congressional Budget Office expects 16 million more uninsured Americans by 2034, while employer health plan costs are projected to rise 11% in 2027.
- Ondine Biomedical's LANTERN Phase 3 pivotal trial met its primary efficacy endpoint, with nasal photodisinfection plus standard of care associated with an estimated 40% relative reduction in 30-day surgical site infections versus standard of care alone. - The study enrolled 5,188 patients across 18 hospitals in the United States and Canada, with no treatment-related serious safety concerns identified in the topline review. - Ondine plans to request a pre-New Drug Application meeting with the FDA and will present detailed findings at a scientific meeting and in peer-reviewed journals. - The non-antibiotic technology offers a potential approach to SSI prevention amid rising antibiotic resistance, with U.S. SSI costs estimated at $3.5–10 billion annually.
- OpenAI's latest free model, GPT-5.5 Instant, scored better than physician-written answers on HealthBench, a benchmark developed with over 260 physicians to evaluate AI health capabilities. - More than 230 million people globally use ChatGPT for health and wellness queries weekly, making healthcare one of OpenAI's most important verticals according to health strategy lead Nate Gross. - A Nature Medicine study of ChatGPT Health found it failed to recommend hospital visits when medically necessary in over half of cases, though OpenAI disputed the methodology. - OpenAI has partnered with eight major health systems including Cedars-Sinai and HCA Healthcare, while Labcorp launched an AI-powered app using OpenAI's models for lab result interpretation.
- Commercial healthcare costs are projected to rise 9% in 2027, the highest medical cost trend in nearly two decades, according to PwC's analysis of 27 health plans covering over 103 million members. - Nearly 70% of surveyed health plans ranked providers' use of AI documentation and coding tools as a top-three cost inflator, with about 20% calling AI the number one inflationary trend. - Blue Cross Blue Shield analysis found approximately $663 million in inpatient spending and $1.67 billion in outpatient spending may be tied to AI-powered coding practices. - Experts note that AI follows existing fee-for-service incentives, increasing documentation and coding severity before it can potentially reduce costs through administrative automation.
- The University of Houston announced the launch of UH Health, an academic health enterprise integrating education, research, and community engagement across multiple health disciplines. - UH Health brings together medicine, nursing, pharmacy, optometry, psychology, social work, and population health under an interprofessional, team-based care model. - The initiative addresses Texas' healthcare workforce shortage, with 64% of hospitals reporting reduced services due to staffing gaps, according to the Texas Hospital Association. - UH is investing $77 million in a new 55,000-square-foot medical research building to expand interdisciplinary research, with completion expected by summer 2028.
- UNC Health has submitted a Certificate of Need application to North Carolina DHHS for a 92-bed hospital near downtown Asheville, with a hearing scheduled for August and a final decision expected in December. - The proposed Asheville facility would offer emergency care, intensive care, neonatology, cardiology, gastroenterology, radiology, psychiatry, and other specialty services on a 21.5-acre site near Westgate Mall. - UNC Health also unveiled plans for a new community hospital in Wilmington on a 62-acre site at South 17th Street and Shipyard Boulevard, targeting a 2030 opening date pending regulatory approvals. - Both proposals aim to address growing regional demand and provide more healthcare choice, with UNC Health CEO Dr. Cristy Page emphasizing the goal of delivering "care closer to home."
- Ondine Biomedical's Phase 3 LANTERN trial has achieved 93% enrollment, bringing the company closer to FDA submission for its non-antibiotic nasal photodisinfection technology Steriwave. - The study involves over 5,000 surgical patients across 14 HCA Healthcare hospitals in the US and four Canadian centers, investigating Steriwave as an alternative to antibiotic mupirocin for preventing surgical site infections. - Steriwave offers a five-minute, nurse-administered treatment with 100% adherence, addressing the $35 billion annual cost of healthcare-associated infections in the US. - Top-line results are expected in Spring 2026, with the technology already approved and utilized in hospitals across the UK, EU, and Canada.
- The FDA has approved Micro Interventional Devices' MIA-T system for pivotal clinical trial use, marking a significant milestone for percutaneous tricuspid valve repair technology. - The STTAR-US trial will evaluate MIA-T's proprietary PolyCor anchors that reduce annular area and minimize tricuspid regurgitation through 12F delivery catheters. - The device addresses a major unmet need, as 1.6 million Americans suffer from tricuspid regurgitation but only a small percentage are eligible for surgical treatment. - MIA-T is positioned to capture part of the rapidly growing transcatheter tricuspid valve repair market, projected to exceed $3 billion annually by 2027.
- Cardiovascular disease experts emphasize the need for a team-based approach to prevention, with cardiologists collaborating with endocrinologists, nephrologists, and liver specialists to address interconnected cardiovascular-kidney-metabolic health risks. - Lipoprotein(a) testing remains severely underutilized with fewer than 1% of patients tested despite being 6 times more atherogenic than LDL cholesterol, prompting new National Lipid Association guidelines recommending lifetime testing for all adults. - Major barriers to cardiovascular prevention include delayed intervention after disease onset and limited access to care, particularly in rural areas where patients face both physician shortages and insurance coverage challenges. - Personalized risk assessment tools and lifestyle interventions require better insurance coverage and practical implementation strategies, with experts advocating for incremental exercise goals starting as low as 5 minutes daily to improve patient adherence.
- Ambry Genetics' CARE Program demonstrated 99.5% accuracy in interpreting NCCN Clinical Practice Guidelines for hereditary cancer risk assessment in a peer-reviewed study published in the Journal of the National Comprehensive Cancer Network. - The digital tool successfully identified 398 out of 400 real-world patient cases that met hereditary cancer testing criteria, matching the assessments of certified genetic counselors. - The HIPAA-compliant platform integrates with electronic health records and streamlines hereditary cancer risk assessment, addressing the gap where approximately 5% of individuals have cancer predisposition gene mutations but most remain unaware.
